Quantcast

Latest Sirolimus Stories

2010-05-07 13:45:00

SAN DIEGO, May 7 /PRNewswire/ -- Patients treated with the Zilver® PTX(TM) Drug-Eluting Peripheral Stent maintained clinical improvement at two years, according to interim results from the Zilver® PTX(TM) Global Registry presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd Annual Scientific Sessions. The prospective, single-arm study is ongoing to evaluate the drug-eluting stent for...

2010-04-02 09:18:04

Rapamycin proves mettle in second model of memory-robbing disease If research results continue to be repeated and are turned into clinical trials, a drug already approved for some uses could be marshaled "” sooner than we expect "” to prevent Alzheimer's disease in humans and improve health to the end of life. A few weeks after a report that rapamycin, a drug that extends lifespan in mice and that is currently used in transplant patients, curbed the effects of Alzheimer's disease...

2010-03-25 13:23:39

Sirolimus-based immunosuppression and radiofrequency ablation are promising treatments for HCC A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver...

2010-03-17 14:08:00

WATERLOO, Belgium, March 17, 2010 /PRNewswire/ -- - SORT OUT III Data Presented at American College of Cardiology Meeting in Atlanta and Published in the Lancet Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER(R) Sirolimus-eluting Coronary Stent and Medtronic's Endeavor(R) Stent highlighting significant and sustained clinical differences. These important findings were presented at the American College of Cardiology annual...

2010-03-17 11:11:29

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect. According to the study team, this discovery has broad clinical implications in the fight against cancer and could affect treatment of lymphoma and many other forms of the disease, including prostate cancer, breast cancer, colorectal...

2010-02-25 08:14:22

Study suggests potential new use for immunosuppressive drug Rapamycin, a drug that keeps the immune system from attacking transplanted organs, may have another exciting use: fighting Alzheimer's disease. Rapamycin rescued learning and memory deficits in a mouse model of Alzheimer's, a team from The University of Texas Health Science Center at San Antonio reported Tuesday (Feb. 23). The study, in the Journal of Biological Chemistry, offers the first evidence that the drug is able to reverse...

2010-02-04 08:00:00

JAMAICA PLAIN, Mass., Feb. 4 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD). The Phase I study, "A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients with Advanced Neovascular Age-Related Macular Degeneration"...

2010-01-25 15:38:02

 Research performed at UC Santa Barbara points to the drug rapamycin as a potential treatment for kidney disease. The study builds on past research and shows that studies performed on mice are more likely to translate to humans than previously thought. The results are published in the current online issue of the Journal of the American Society of Nephrology. Over 600,000 people in the U.S., and 12 million worldwide, are affected by the inherited kidney disease known as ADPKD, short for...

ad5d02e6dacc29a83da644044fdb273f1
2010-01-10 14:03:33

Tuberous sclerosis, commonly associated with autism, is linked to defects in axon guidance Studying a rare disorder known as tuberous sclerosis complex (TSC), researchers at Children's Hospital Boston add to a growing body of evidence suggesting that autism spectrum disorders, which affect 25 to 50 percent of TSC patients, result from a miswiring of connections in the developing brain, leading to improper information flow. The finding may also help explain why many people with TSC have...

2010-01-05 07:00:00

LA JOLLA, Calif., Jan. 5 /PRNewswire/ -- Intellikine, Inc. has initiated a Phase I clinical trial for its targeted anticancer drug INK128, a novel orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway. "Advancing INK128 to this point is a significant achievement for Intellikine," said Troy Wilson, Ph.D., J.D., President and CEO of Intellikine. "INK128 is the first drug resulting from our internal discovery...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.